F. Morschhauser

D. Huglo, B. Hivert, J. Rossignol, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

B. Coiffier, H. Lelièvre, S. Depil, 2015, Investigational New Drugs.

Final Results of a Phase I Study of the Anti-CD79b Antibody-Drug Conjugate DCDS4501A (Polatuzumab Vedotin) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 4400

R. Advani, G. Salles, M. Czuczman, 2013 .

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

P. Gaulard, H. Tilly, L. de Leval, 2011, Blood.

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.

F. Lemonnier, P. Staber, M. Davids, 2021, Blood.

Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides.

P. Martiat, F. Morschhauser, P. Lewalle, 1997, Blood.

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

K. Tarte, P. Hagner, S. Carrancio, 2019, British journal of haematology.

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

A. Hagenbeek, G. Salles, J. Radford, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

P. Zinzani, C. Dumontet, F. Morschhauser, 2007, Leukemia & lymphoma.

Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

D. Goldenberg, F. Morschhauser, W. Wegener, 2010, Leukemia & lymphoma.

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.

D. Huglo, M. Pfreundschuh, L. Trümper, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

G. Salles, A. Fischer, É. Oksenhendler, 2006, Blood.

Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study

Wan-Jen Hong, F. Morschhauser, M. Palomba, 2021, Clinical Lymphoma Myeloma and Leukemia.

Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study

B. Quesnel, I. Yakoub-Agha, P. Fenaux, 2002, Bone Marrow Transplantation.

Angioimmunoblastic T‐cell Lymphoma

F. Morschhauser, J. Dupuis, 2021, The Peripheral T‐Cell Lymphomas.

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.

H. Stein, D. Huglo, R. Marcus, 2007 .

Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

G. Salles, H. Tilly, N. Milpied, 2009 .

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

D. Maloney, F. Hernandez-Ilizaliturri, Timothy R. Mack, 2022, The Lancet.

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

S. Pileri, P. Pauwels, P. Zinzani, 2021, Cancer.

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

G. Salles, M. Bacac, C. Carlo-Stella, 2021, Journal of Clinical Oncology.

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

R. Houot, I. Yakoub-Agha, L. Fornecker, 2017, Blood.

Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies

R. Houot, O. Casasnovas, L. Dercle, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.

J. Burke, G. Salles, A. Melnick, 2022, Blood reviews.

Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.

S. Genay, P. Odou, J. Goossens, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group

G. Salles, R. Bouabdallah, C. Sebban, 2016, Haematologica.

The Lymphoid Variant of Hypereosinophilic Syndrome

G. Salles, A. Baruchel, M. Copin, 2014, Medicine.

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

G. Salles, M. Gleeson, P. Hérait, 2014 .

INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS

G. Salles, J. Radford, H. Tilly, 2017 .

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

T. Molina, F. Jardin, G. Salles, 2011, The Lancet.

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

C. Gisselbrecht, P. Borchmann, J. Harousseau, 2003, Haematologica.

lymphoma patients: results of the GELA-GOELAMS FL2000 study Rituximab combined with chemotherapy and interferon in follicular

J. Rossi, G. Salles, R. Bouabdallah, 2013 .

ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.

B. Coiffier, N. Mounier, P. Lugtenburg, 2012 .

Controversies in the Treatment of Peripheral T-cell Lymphoma

P. Gaulard, P. Zinzani, L. de Leval, 2020, HemaSphere.

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

B. Coiffier, S. Horwitz, H. Prince, 2014, Journal of Hematology & Oncology.

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

B. Coiffier, C. Haioun, J. Gabarre, 2013, European journal of cancer.

Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma

F. Morschhauser, E. Boyle, 2015, Expert opinion on drug safety.

Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma

C. Preudhomme, C. Maurage, S. Tricot, 2015, British journal of haematology.

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

P. Gaulard, L. de Leval, P. Staber, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.

S. Stilgenbauer, L. Gelbert, S. Buchanan, 2020, Haematologica.

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

E. Campo, S. Pileri, J. Radford, 2017, British journal of haematology.

[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

G. Salles, I. Yakoub-Agha, F. Morschhauser, 2017, Bulletin du Cancer.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2016, Hematological oncology.

EFFICACY AND SAFETY OF RITUXIMAB IN B-CELL POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: RESULTS OF A PROSPECTIVE MULTICENTRE PHASE II STUDY Running head: Rituximab in PTLD

G. Salles, A. Fischer, É. Oksenhendler, 2017 .

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Sam A. Mayes, F. Jardin, D. Huglo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

R. Bouabdallah, O. Casasnovas, M. Mohty, 2014, Annals of Hematology.

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

G. Salles, R. Bouabdallah, P. Feugier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

G. Salles, H. Tilly, P. Solal-Céligny, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

B. Coiffier, O. Casasnovas, H. Tilly, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B )

er, O. Casasnovas, H. Tilly, 2013 .

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

phase 2 study lymphoproliferative disorders: results of a prospective multicenter Efficacy and safety of rituximab in B-cell post-transplantation

G. Salles, A. Fischer, É. Oksenhendler, 2011 .

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

T. Molina, F. Jardin, G. Salles, 2011, The Lancet.

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab‐naive, recurrent/refractory follicular non‐Hodgkin lymphoma with high tumor burden

M. Copin, P. Feugier, H. Tilly, 2010, Cancer.

A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

P. Borchmann, J. Harousseau, R. Herbrecht, 2003 .

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.

V. Diehl, M. Sieber, F. Morschhauser, 2003, Blood.

Treatment of relapsed CD 20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated : results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

V. Diehl, M. Sieber, T. Rüdiger, 2002 .

Study Group (GHSG) Long-term results of a phase-II trial of the German Hodgkin Lymphoma Rituximab in relapsed lymphocyte-predominant Hodgkin Lymphoma:

V. Diehl, T. Rüdiger, P. Borchmann, 2013 .

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

E. Kimby, B. Coiffier, A. Belch, 2007 .

Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.

P. Zinzani, M. Dreyling, B. Childs, 2013, Clinical advances in hematology & oncology : H&O.

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

G. Salles, J. Zaucha, P. Reinke, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy (RIT) of Refractory or Relapsed Hodgkin’s Lymphoma (HL) with 90Yttrium-Labelled Antiferritin Antibody.

D. Decaudin, F. Morschhauser, A. Pecking, 2007 .

Glomerular injury in chronic myelomonocytic leukemia.

E. Wattel, P. Fenaux, F. Bauters, 1995, Leukemia & lymphoma.

Neutropenia in patients treated with rituximab.

P. Solal-Céligny, F. Morschhauser, E. Voog, 2003, The New England journal of medicine.

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)

C. Preudhomme, P. Fenaux, F. Bauters, 2005, Leukemia.

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

F. Morschhauser, E. Boyle, L. Renaud, 2020, European journal of haematology.

Clinical/Scientific Notes

K. Hoang-Xuan, B. Kleinschmidt-DeMasters, C. Houillier, 2011, Neurology.

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

J. Gribben, F. Morschhauser, N. Fowler, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

A. Salar, E. W. Van Den Neste, N. Bartlett, 2021, Blood.

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2011 .

Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma

J. Raemaekers, M. Federico, C. Sebban, 2012 .

Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.

F. d'Amore, P. Zinzani, P. Zinzani, 2008, European journal of cancer.

Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.

E. Kimby, G. Salles, C. Flowers, 2022, Clinical lymphoma, myeloma & leukemia.

End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma

M. Federico, R. Marcus, A. Evens, 2022, British journal of haematology.

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

G. Salles, K. Kolibaba, H. Tilly, 2016 .

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up

J. Rossi, G. Salles, R. Bouabdallah, 2007 .

Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.

A. Hagenbeek, R. Bouabdallah, F. Morschhauser, 2005 .

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

R. Houot, F. Jardin, K. Hoang-Xuan, 2022, Bone Marrow Transplantation.

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

R. Houot, F. Jardin, K. Hoang-Xuan, 2020, Neurology.

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study

B. Coiffier, H. Tilly, V. Ribrag, 2012 .

Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial.

O. Casasnovas, M. Callanan, C. Bodet-Milin, 2020, Blood.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Michael L. Wang, O. Casasnovas, P. Zinzani, 2019, Leukemia.

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

P. Gaulard, L. de Leval, P. Staber, 2020 .

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

F. Cavalli, B. Coiffier, H. Tilly, 2017 .

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

G. Salles, E. Campo, F. Cavalli, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

R. Houot, C. Copie-Bergman, B. Coiffier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

L. Sehn, I. Flinn, L. Xerri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study

R. Bouabdallah, O. Casasnovas, P. Feugier, 2020 .

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

J. Gribben, G. Salles, L. Sehn, 2015, Blood.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

G. Salles, O. Casasnovas, P. Feugier, 2017, Blood.

A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry

D. Huglo, N. Simon, C. Barthélémy, 2018, Scientific Reports.

Bendamustine is effective in T‐Cell prolymphocytic leukaemia

X. Leleu, L. Ysebaert, B. Cazin, 2015, British journal of haematology.

Validation of the Functional Assessment of Cancer Therapy–Lymphoma (FACT-LYM) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

A. Zimmermann, F. Morschhauser, A. Liepa, 2008 .

Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

A. Stamatoullas, P. Feugier, M. André, 2022, Leukemia & lymphoma.

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

G. Lenz, A. Santoro, A. Nagler, 2018, Blood.

Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)

R. Houot, L. Fornecker, M. André, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

R. Boellaard, M. Kersten, D. de Jong, 2022, Leukemia.

Semiquantitative analysis of residual disease in patients treated for adult T‐cell leukaemia/lymphoma (ATLL)

E. Wattel, I. Leclercq, M. Cavrois, 1999, British journal of haematology.

Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin

J. Burke, F. Morschhauser, J. Sharman, 2020, Expert review of clinical pharmacology.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

R. Houot, F. Jardin, K. Hoang-Xuan, 2016, Neuro-oncology.

Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma

B. Coiffier, D. Huglo, A. Versari, 2012 .

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

B. Coiffier, F. d'Amore, J. Radford, 2014 .

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

R. Advani, G. Salles, L. Sehn, 2013 .

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

B. Coiffier, J. Jais, C. Haioun, 2011, Blood.

Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma

Maximilien Vermandel, Nacim Betrouni, Marc Steinling, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y

D. Huglo, F. Kraeber-Bodéré, J. Chatal, 2008 .

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.

R. Houot, G. Salles, K. Hoang-Xuan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

T. Molina, F. Jardin, B. Coiffier, 2010 .

SEQUENTIAL TREATMENT WITH RITUXIMAB AND CHOP CHEMOTHERAPY IN B-CELL PTLD – WILL RISK STRATIFIED SEQUENTIAL TREATMENT BECOME THE NEW STANDARD IN THERAPY?: 292

G. Salles, B. Dörken, P. Reinke, 2008 .

Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.

R. Houot, G. Salles, R. Bouabdallah, 2021, Blood.

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

K. Hoang-Xuan, O. Chinot, R. Gressin, 2019, Annals of Oncology.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

R. Bouabdallah, M. Hallek, V. Leblond, 2014, Blood.

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

G. Salles, M. Bacac, C. Carlo-Stella, 2018, Blood.

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

B. Coiffier, S. Horwitz, H. Prince, 2010 .

Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL)

B. Coiffier, H. Tilly, V. Ribrag, 2011 .

Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls.

P. Devos, D. Dewailly, C. Decanter, 2018, Reproductive biomedicine online.

Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results.

D. Dewailly, C. Decanter, F. Morschhauser, 2010, Reproductive biomedicine online.

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

G. Salles, H. Tilly, N. Brousse, 2006 .

Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo

B. Payrastre, L. Ysebaert, F. Morschhauser, 2020, Journal of thrombosis and haemostasis : JTH.

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

C. Flowers, S. de Vos, I. Dimery, 2017, Blood.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.

M. Kersten, J. Radford, R. Malladi, 2022, Blood.

Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.

V. Ribrag, J. Westin, F. Morschhauser, 2021, Clinical lymphoma, myeloma & leukemia.

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

G. Salles, J. Radford, H. Tilly, 2020, The Lancet. Oncology.

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

A. Zelenetz, J. Delgado, A. Schuh, 2019, Health and Quality of Life Outcomes.

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

V. Ribrag, C. D. de Boer, F. Morschhauser, 2015, Clinical Cancer Research.

A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

R. Greil, G. Salles, A. Zelenetz, 2020, Blood.

A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

T. Molina, F. Jardin, G. Salles, 2020, Clinical Cancer Research.

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

J. Gribben, G. Salles, R. Bouabdallah, 2018, Blood.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

R. Greil, P. Gaulard, G. Salles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

G. Salles, J. Radford, A. Mcdonald, 2016 .

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

G. Salles, M. Gleeson, A. Palumbo, 2016, The Lancet. Haematology.

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, G. Salles, B. Coiffier, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

R. Greil, M. Kersten, I. Flinn, 2021, The New England journal of medicine.

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

G. Salles, P. Reinke, H. Lehmkuhl, 2012, The Lancet. Oncology.

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

G. Salles, B. Coiffier, H. Dombret, 2016, The Lancet.

Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.

C. Decanter, F. Morschhauser, J. Labreuche, 2021, Human reproduction.

Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.

D. Dewailly, C. Decanter, F. Morschhauser, 2014, Fertility and sterility.

Testicular natural killer T‐cell lymphoma

A. Villers, L. Lemaitre, J. Fantoni, 2005, International journal of urology : official journal of the Japanese Urological Association.

Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

A. Hagenbeek, A. Rohatiner, J. Kuhlmann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo

R. Boellaard, A. Lammertsma, G. V. van Dongen, 2019, The Journal of Nuclear Medicine.

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

L. Obéric, L. Ysebaert, T. Filleron, 2018, American journal of hematology.

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

S. Horning, T. Illidge, A. Younes, 2013, Leukemia & lymphoma.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

G. Salles, J. Machiels, D. Cunningham, 2019, Molecular Cancer Therapeutics.

Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.

V. Diehl, M. Dietlein, H. Schicha, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel targeted agents for follicular lymphoma

F. Morschhauser, C. Batlevi, 2021 .

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

R. Houot, M. Mohty, J. Bay, 2022, Nature Medicine.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

G. Salles, M. Dyer, C. Fegan, 2016, Blood.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

G. Salles, L. Sehn, A. López-Guillermo, 2018, The New England journal of medicine.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Matthew Greenwood, Martin Wilhelm, B. Coiffier, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.

G. Salles, A. Stamatoullas, O. Casasnovas, 2009, Blood.

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Sonali M. Smith, L. Gordon, T. Habermann, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Antibody Therapies for Patients With Diffuse Large B-cell Lymphoma: What Does the Future Hold?

L. Sehn, A. López-Guillermo, F. Morschhauser, 2020 .

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

R. Advani, G. Salles, M. Czuczman, 2015, Leukemia.

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.

R. Houot, G. Salles, L. Xerri, 2020, Blood advances.

CD3−CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

G. Salles, M. Copin, C. Preudhomme, 2015, Haematologica.

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

D. Huglo, S. Fanti, C. Fonti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

R. Houot, B. Coiffier, R. Bouabdallah, 2016, British journal of haematology.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Michael L. Wang, O. Casasnovas, P. Zinzani, 2017, The Lancet.

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.

C. Copie-Bergman, F. Jardin, A. López-Guillermo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

infection and outcome variations in the tumor microenvironment and correlations with EBV Molecular profiling of classical Hodgkin lymphoma tissues uncovers

T. Molina, F. Bertucci, D. Birnbaum, 2013 .

Oligoclonal proliferation of human T‐cell leukaemia virus type 1 bearing T cells in adult T‐cell leukaemia/lymphoma without deletion of the 3′ provirus integration sites

E. Wattel, I. Leclercq, M. Cavrois, 1998, British journal of haematology.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

R. Bouabdallah, A. Stamatoullas, P. Feugier, 2019, The Lancet. Oncology.

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

G. Lenz, A. Santoro, A. Nagler, 2019, American journal of hematology.

Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma

R. Houot, F. Jardin, G. Salles, 2017, The New England journal of medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

A. Hagenbeek, G. Salles, F. d'Amore, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome

I. Buvat, O. Casasnovas, J. Clerc, 2019, The Journal of Nuclear Medicine.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

J. Jais, P. Feugier, H. Tilly, 2017, Blood.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

J. Friedberg, I. Flinn, Y. Oki, 2014, The Lancet. Oncology.

Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

T. Molina, B. Coiffier, J. Jais, 2014 .

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

G. Salles, O. Casasnovas, P. Feugier, 2011, Haematologica.

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

G. Salles, J. Radford, R. Marcus, 2013, Blood.

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

B. Coiffier, H. Tilly, C. Gisselbrecht, 2011, Clinical lymphoma, myeloma & leukemia.

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

A. Zelenetz, B. Coiffier, J. Delgado, 2017 .

High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B

C. Copie-Bergman, G. Salles, P. Brousset, 2021, The American journal of surgical pathology.

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.

E. Kimby, E. Hoster, A. Hagenbeek, 2021, Blood advances.

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

G. Salles, R. Bouabdallah, L. Xerri, 2017, Human pathology.

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

T. Molina, F. Jardin, G. Salles, 2013, Leukemia.

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.

J. Rossi, G. Salles, G. Delsol, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Radioimmunotherapy in follicular lymphoma.

T. Illidge, F. Morschhauser, 2011, Best practice & research. Clinical haematology.

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

R. Houot, G. Salles, P. Feugier, 2013, Haematologica.

18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients

I. Buvat, L. Vercellino, O. Casasnovas, 2022, The Journal of Nuclear Medicine.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

J. Radford, L. Trümper, L. Arcaini, 2016, The Lancet. Oncology.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

E. Kimby, G. Salles, A. López-Guillermo, 2018, The Lancet. Haematology.

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

J. Raemaekers, M. Pfreundschuh, H. Tilly, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

F. Jardin, H. Tilly, S. Chevret, 2014, Genes, chromosomes & cancer.

Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies

Claude Auriault, S. Depil, B. Maillère, 2007, Journal of immunotherapy.

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

P. Gaulard, F. d'Amore, L. de Leval, 2022, Blood.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

P. Zinzani, D. Cunningham, G. Verhoef, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.

A. Rohatiner, M. Dreyling, F. Morschhauser, 2009, The oncologist.

CXCL13 is expressed in various haematological disorders other than angioimmunoblastic T-cell lymphoma.

M. Copin, F. Morschhauser, G. Lefèvre, 2020, Pathology, research and practice.

Kinase Inhibitors in Large Cell Lymphoma

F. Morschhauser, S. Manier, N. Fowler, 2018, Künstliche Photosynthese.

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

G. Salles, M. Dyer, C. Fegan, 2017, Blood.

Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.

F. Morschhauser, E. Boyle, C. Herbaux, 2018, Current research in translational medicine.

Total immunotherapy for Hodgkin lymphoma.

R. Houot, F. Morschhauser, R. Merryman, 2020, The Lancet. Haematology.

Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study

I. Flinn, D. Ramies, T. Phillips, 2021 .

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

G. Lenz, A. Santoro, A. Nagler, 2017 .

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

G. Salles, L. Sehn, G. Fingerle-Rowson, 2014 .

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

G. Salles, B. Cheson, M. Dyer, 2016 .

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

A. Zelenetz, J. Delgado, S. Stilgenbauer, 2016 .

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

D. Cunningham, M. Dreyling, B. Childs, 2014 .

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

E. Hachulla, L. Mortier, D. Launay, 2020, Oncoimmunology.

Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

G. Salles, M. Hallek, S. Stilgenbauer, 2015 .

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

R. Greil, J. Burke, G. Salles, 2021, The New England journal of medicine.

FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES

R. Houot, E. Gat, S. Choquet, 2021, Hematological Oncology.

High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP.

L. Vercellino, P. Gaulard, G. Salles, 2020, Blood.

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

M. Kersten, A. Hagenbeek, D. de Jong, 2020, Haematologica.

Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study

R. Garnier, C. Haioun, Y. Esquirol, 2021, International journal of environmental research and public health.

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

G. Salles, C. Haioun, L. Fornecker, 2021, BMC Public Health.

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

J. Zaucha, N. Bartlett, T. Phillips, 2021, Blood.

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

J. Zaucha, N. Bartlett, T. Phillips, 2022, Blood.

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

R. Houot, L. Ysebaert, E. Gat, 2021, Blood.

Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis.

L. Vercellino, R. Houot, O. Casasnovas, 2022, Blood.

Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.

D. Huglo, T. Illidge, C. Bodet-Milin, 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy.

I. Yakoub-Agha, R. Nyga, A. Moreau, 2021, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

G. Salles, L. Sehn, J. Friedberg, 2019, Journal of Clinical Oncology.

Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

R. Advani, A. Hagenbeek, G. Salles, 2014 .

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

J. Leonard, B. Coiffier, D. Goldenberg, 2005 .

Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment

F. Lemonnier, F. Morschhauser, Gamze Tari, 2021, Current opinion in oncology.

MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome

B. Quesnel, E. Bertrand, C. Preudhomme, 2014, British journal of haematology.

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

R. Greil, G. Salles, A. Zelenetz, 2021, Blood.

90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

R. Greil, P. Gaulard, B. Coiffier, 2019, British journal of haematology.

Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network

K. Hoang-Xuan, O. Chinot, R. Gressin, 2016 .

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

L. Ysebaert, F. Morschhauser, 2011, Expert opinion on investigational drugs.

International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial

G. Salles, P. Schlattmann, J. Zaucha, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

G. Salles, J. Zaucha, P. Reinke, 2015 .

Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial

G. Salles, P. Schlattmann, P. Reinke, 2013, Leukemia.

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

G. Salles, M. Dyer, J. Radford, 2020, Leukemia.

Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials

J. Zaucha, P. Reinke, N. Babel, 2018, Transplantation.

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

C. Carlo-Stella, M. Hutchings, E. Clark, 2022, The New England journal of medicine.

Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC

R. Houot, I. Yakoub-Agha, L. Fornecker, 2015 .

Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant

B. Coiffier, P. Feugier, H. Tilly, 2011, Leukemia & lymphoma.

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

B. Coiffier, J. Jais, O. Casasnovas, 2007 .

RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.

G. Salles, A. López-Guillermo, R. Bouabdallah, 2018 .

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

G. Salles, R. Bouabdallah, J. Jais, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

G. Salles, J. Radford, R. Marcus, 2011 .

K. Hoang-Xuan, O. Chinot, R. Gressin, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

K. Savage, P. Zinzani, S. Horwitz, 2022, Blood advances.

Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.

R. Bouabdallah, H. Tilly, C. Gisselbrecht, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

O. Casasnovas, M. André, M. Meignan, 2022, Diagnostics.

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

P. Feugier, H. Tilly, C. Haioun, 2021, Cancers.

Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999)

G. Salles, F. Morschhauser, G. Cartron, 2010 .

Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline 18F-FDG PET-CT

D. Huglo, F. Morschhauser, C. Herbaux, 2020, Leukemia & lymphoma.

Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, G. Salles, A. Stamatoullas, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.

A. Hagenbeek, G. Salles, J. Radford, 2007 .

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.

H. Stein, D. Huglo, R. Marcus, 2004 .

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Sonali M. Smith, L. Gordon, T. Habermann, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456)

B. Coiffier, R. Bouabdallah, H. Holte, 2013 .

Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST).

J. Zaucha, P. Reinke, H. Lehmkuhl, 2012 .

[Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment)].

F. Morschhauser, E. Guardiola, É. Antoine, 2007, Bulletin du cancer.

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

C. Flowers, I. Dimery, F. Morschhauser, 2016 .

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2021, Cancer.

Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2019, Cancer.

Immunomodulatory Agents in Follicular Lymphoma.

L. Ysebaert, F. Morschhauser, 2020, Hematology/oncology clinics of North America.

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

R. Houot, C. Haioun, T. Phillips, 2021, Blood.

EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

I. Lossos, G. Salles, O. Casasnovas, 2019, Hematological Oncology.

for the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

R. Houot, G. Salles, P. Feugier, 2013 .

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

E. Piccione, C. Carlo-Stella, M. Crump, 2020 .

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil, J. Burke, G. Salles, 2021, Blood.

INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

G. Salles, J. Radford, H. Tilly, 2019, Hematological Oncology.

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.

K. Tarte, R. Houot, T. Fest, 2021, Blood advances.

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

J. Friedberg, I. Flinn, Y. Oki, 2013 .

New strategies with 90Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma and mantle cell lymphoma

F. Morschhauser, 2009 .

New strategies with 90 Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma and mantle cell lymphoma

F. Morschhauser, 2007 .

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study

P. Gaulard, G. Salles, J. Jais, 2023, British journal of haematology.

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

G. Salles, L. Sehn, A. López-Guillermo, 2019, Blood.

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.

R. Greil, C. Copie-Bergman, P. Feugier, 2021, Blood advances.

First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study

P. Coppo, F. Morschhauser, E. Gyan, 2020, American journal of hematology.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

P. Zinzani, K. Ardeshna, F. Morschhauser, 2019, Leukemia & lymphoma.

Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

C. Haioun, F. Morschhauser, G. Hess, 2010 .

Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.

B. Coiffier, P. Feugier, H. Tilly, 2005 .

Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy

A. Hagenbeek, J. Radford, F. Morschhauser, 2005 .

RISK STRATIFIED SEQUENTIAL TREATMENT WITH RITUXIMAB AND CHOP CHEMOTHERAPY IN B-CELL PTLD - DEFINING A NEW STANDARD OF CARE: RESULTS FROM A PROSPECTIVE INTERNATIONAL MULTICENTER TRIAL: 1322

G. Salles, J. Zaucha, P. Reinke, 2010 .

Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

B. Coiffier, S. Horwitz, H. Prince, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012 .

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

G. Salles, R. Bouabdallah, P. Feugier, 2011 .

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

K. Tarte, R. Houot, L. Xerri, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

J. Leonard, T. Phillips, P. McKay, 2022, Blood.

Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.

I. Lossos, G. Salles, O. Casasnovas, 2021 .

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

J. Cerhan, G. Salles, T. Habermann, 2013, Cytokine.

Lack of reproducibility of histopathological features in MYC‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

A. Rosenwald, Y. Natkunam, R. Advani, 2023, Histopathology.

A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY

G. Salles, S. Stilgenbauer, V. Ribrag, 2017 .

Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).

G. Salles, H. Tilly, N. Milpied, 2009 .

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).

J. Friedberg, I. Flinn, Y. Oki, 2013 .

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

R. Houot, M. Mohty, J. Bay, 2021, Blood.

Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): NHL‐133

G. Salles, J. Radford, A. Mcdonald, 2018, Clinical Lymphoma Myeloma and Leukemia.

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

R. Advani, A. Hagenbeek, G. Salles, 2014 .

POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA

C. Haioun, N. Bartlett, C. Lee, 2017 .

A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA (NHL)

F. Morschhauser, M. Palomba, G. Cartron, 2017 .

First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL)

E. Noordijk, M. Henry-Amar, F. Morschhauser, 2005 .

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.

I. Yakoub-Agha, E. Alidjinou, F. Morschhauser, 2023, British Journal of Haematology.

R. Houot, G. Vassal, L. Brugières, 2017 .

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

A. Stamatoullas, V. Edeline, V. Ribrag, 2019, Blood.

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

M. Kersten, A. Hagenbeek, J. Zijlstra, 2018, Blood.

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

J. Szer, J. Abramson, F. Morschhauser, 2017, Leukemia & lymphoma.

[Indications of G-CSF administration in hematologic disorders].

F. Bauters, F. Morschhauser, V. Coiteux, 2006, Bulletin du cancer.

POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL

G. Salles, J. Friedberg, M. Trněný, 2019, Hematological Oncology.

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

G. Salles, J. Radford, H. Tilly, 2019, Blood.

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

G. Salles, R. Morin, J. Radford, 2017 .

A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease

G. Salles, H. Tilly, N. Milpied, 2008 .

Impact of Anti-CD20 Antibodies on the Incidence of Secondary Cancers in Patients Treated for Chronic Lymphocytic Leukemia

B. Cazin, T. Facon, F. Morschhauser, 2015 .

A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry

D. Huglo, N. Simon, C. Barthélémy, 2018, Scientific Reports.

Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study

G. Salles, A. López-Guillermo, R. Bouabdallah, 2011 .

A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma

R. Houot, G. Salles, H. Tilly, 2014 .

Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.

T. Molina, G. Salles, R. Bouabdallah, 2013, Clinical advances in hematology & oncology : H&O.

Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas

P. Gaulard, F. Lemonnier, C. Haioun, 2016 .

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

M. Wei, N. Gutiérrez, L. Ysebaert, 2021, Blood.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

F. Hernandez-Ilizaliturri, K. Izutsu, M. Lunning, 2022, Blood.

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.

C. Carlo-Stella, M. Hutchings, E. Clark, 2022, Journal of Clinical Oncology.

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.

G. Salles, B. Dörken, J. Zaucha, 2009 .

Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].

A. Baruchel, I. Yakoub-Agha, J. Bay, 2021, Bulletin du cancer.

The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma

T. Molina, E. Macintyre, N. Cerf-Bensussan, 2021, Blood.

REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM

R. Houot, G. Salles, H. Tilly, 2019, Hematological Oncology.

S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

R. Houot, G. Salles, H. Tilly, 2019, HemaSphere.

Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma

M. Pfreundschuh, C. Caldwell, S. Stilgenbauer, 2014 .

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)

G. Salles, R. Bouabdallah, P. Feugier, 2010 .

Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.

F. d'Amore, J. Radford, H. Tilly, 2007 .

CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.

N. Bartlett, M. Wei, Sung-Soo Yoon, 2022, Journal of Clinical Oncology.

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

A. López-Guillermo, F. Bosch, M. Dickinson, 2022, Blood.

Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma

K. Lechner, K. Korfi, C. Carlo-Stella, 2022, Blood.

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

R. Houot, F. Bosch, K. Lechner, 2022, Blood.

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

E. Piccione, N. Bartlett, C. Carlo-Stella, 2022, Blood.

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography

D. Huglo, B. Dupas, C. Bodet-Milin, 2008, Haematologica.

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

G. Salles, I. Yakoub-Agha, F. Morschhauser, 2017, Bulletin du cancer.

Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen

L. Xerri, B. Tesson, C. Chassagne‐Clément, 2023, British journal of haematology.

Heterogeneity of protein kinase C β2 expression in lymphoid malignancies

C. Dumontet, A. Decouvelaere, F. Morschhauser, 2007, Histopathology.

THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

E. Kimby, G. Salles, S. Montoto, 2017 .

Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

P. Feugier, M. André, E. Durot, 2021, Blood.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

R. Greil, M. Kersten, Y. Kwong, 2021, New England Journal of Medicine.

A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA

R. Houot, G. Salles, R. Bouabdallah, 2017 .

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

G. Salles, A. Santoro, G. Follows, 2017 .

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

A. Rosenwald, M. Ziepert, T. Molina, 2023, Blood advances.

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

J. Gribben, G. Salles, J. Radford, 2018, Blood.

Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.

G. Salles, P. Reinke, H. Lehmkuhl, 2007 .

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

R. Advani, K. Savage, P. Zinzani, 2019, Blood.

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

G. Salles, P. Reinke, H. Lehmkuhl, 2011 .

Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.

G. Salles, L. Sehn, A. Zelenetz, 2016 .

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors.

J. Machiels, D. Cunningham, A. Awada, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Michael L. Wang, P. Zinzani, E. Jacobsen, 2017 .

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, P. Zinzani, 2020 .

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

J. Gribben, F. Morschhauser, J. Seymour, 2022, Blood.

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.

F. Bosch, M. Dickinson, F. Morschhauser, 2023, Journal of Clinical Oncology.

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.

A. Salar, N. Bartlett, C. Carlo-Stella, 2023, Journal of Clinical Oncology.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil, J. Burke, G. Salles, 2021, New England Journal of Medicine.

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

G. Salles, M. Dyer, C. Fegan, 2016 .

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

I. Flinn, L. Arcaini, C. Visco, 2022, Blood.

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

James G. Wright, M. Dyer, C. Fegan, 2013 .

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

James G. Wright, G. Salles, M. Dyer, 2013 .

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

G. Salles, L. Sehn, A. Zelenetz, 2016 .

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

G. Salles, M. Hallek, G. Lozanski, 2016 .

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

G. Salles, M. Bacac, C. Carlo-Stella, 2019, Blood.

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

B. Coiffier, T. Lister, P. Zinzani, 2005 .

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

K. Tarte, R. Houot, O. Casasnovas, 2023, Nature Medicine.

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

R. Greil, G. Salles, A. Zelenetz, 2018, Blood.

OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL

O. Casasnovas, A. Davies, F. Morschhauser, 2017 .

Angioimmunoblastic T‐cell Lymphoma

F. Morschhauser, J. Dupuis, 2021, The Peripheral T‐Cell Lymphomas.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

B. Coiffier, F. d'Amore, M. Federico, 2014, Cancer treatment reviews.

B. Coiffier, C. Haioun, J. Gabarre, 2013, European journal of cancer.

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

J. Gribben, F. Morschhauser, N. Fowler, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

R. Houot, O. Casasnovas, M. Mohty, 2023, Blood advances.

18F-FDG-PET dissemination features in diffuse large B cell lymphoma are predictive of outcome

O. Casasnovas, M. Meignan, C. Nioche, 2019 .

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

B. Coiffier, J. Jais, C. Haioun, 2011, Blood.

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

A. Zelenetz, B. Coiffier, S. Stilgenbauer, 2017, The Lancet. Oncology.

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

A. Zelenetz, B. Coiffier, S. Stilgenbauer, 2017 .

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

R. Houot, G. Salles, P. Feugier, 2018, Leukemia.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

J. Radford, L. Trümper, L. Arcaini, 2016, The Lancet. Oncology.

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

P. Gaulard, H. Tilly, L. de Leval, 2011, Blood.

Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.

F. Jardin, L. Sehn, J. Friedberg, 2023, Journal of Clinical Oncology.

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

O. Casasnovas, P. Chevallier, M. Callanan, 2019, Blood.

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY

O. Casasnovas, P. Zinzani, P. Jain, 2021, Hematological Oncology.

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma versus therapy in

E. Campo, J. Radford, L. Arcaini, 2020 .

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab‐naive, recurrent/refractory follicular non‐Hodgkin lymphoma with high tumor burden

M. Copin, P. Feugier, H. Tilly, 2010, Cancer.

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Michael L. Wang, P. Zinzani, P. Jain, 2020, Blood.

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS

E. Piccione, C. Haioun, C. Carlo-Stella, 2021, Hematological Oncology.

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

K. Tarte, R. Houot, R. Bouabdallah, 2021 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

G. Salles, O. Casasnovas, P. Feugier, 2017, Blood.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study

O. Casasnovas, P. Feugier, C. Haioun, 2020 .

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

J. Leonard, J. Pagel, T. Phillips, 2021, Blood.

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

G. Salles, S. Dave, N. Michaud, 2021, Blood.

Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial.

J. Briones, C. Gisselbrecht, E. Zucca, 2008 .

Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study

G. Salles, C. Volteau, C. Haioun, 2008 .

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.

H. Stein, D. Huglo, R. Marcus, 2007, Blood.

90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

A. Hagenbeek, G. Salles, J. Radford, 2010 .

Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial

L. Vercellino, O. Casasnovas, F. Morschhauser, 2023, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Detection of Non-Hodgkin’s Lymphoma in ovarian cortex pieces during the process of cryopreservation

D. Vinatier, C. Decanter, F. Morschhauser, 2014, Journal of Assisted Reproduction and Genetics.

The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?

R. Houot, F. Jardin, K. Hoang-Xuan, 2016 .

Semiquantitative analysis of residual disease in patients treated for adult T‐cell leukaemia/lymphoma (ATLL)

E. Wattel, I. Leclercq, M. Cavrois, 1999, British journal of haematology.

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program

R. Bouabdallah, A. Stamatoullas, M. Bernard, 2016, Haematologica.